Private Capital Advisors Inc. Sells 94,506 Shares of Immunome, Inc. $IMNM

Private Capital Advisors Inc. reduced its position in Immunome, Inc. (NASDAQ:IMNM) by 80.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,540 shares of the company’s stock after selling 94,506 shares during the quarter. Private Capital Advisors Inc.’s holdings in Immunome were worth $506,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Nan Fung Trinity HK Ltd. increased its holdings in Immunome by 7.9% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 592,103 shares of the company’s stock valued at $6,934,000 after buying an additional 43,253 shares during the period. NEOS Investment Management LLC increased its holdings in Immunome by 40.5% in the 3rd quarter. NEOS Investment Management LLC now owns 162,186 shares of the company’s stock valued at $1,899,000 after buying an additional 46,755 shares during the period. Pivotal bioVenture Partners Investment Advisor LLC bought a new position in Immunome in the 3rd quarter valued at about $5,884,000. TD Asset Management Inc increased its holdings in Immunome by 15.8% in the 3rd quarter. TD Asset Management Inc now owns 701,280 shares of the company’s stock valued at $8,212,000 after buying an additional 95,750 shares during the period. Finally, Principal Financial Group Inc. increased its holdings in Immunome by 222.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company’s stock valued at $12,939,000 after buying an additional 762,147 shares during the period. 44.58% of the stock is owned by institutional investors.

Immunome Trading Down 5.7%

IMNM opened at $21.66 on Friday. The company’s 50 day moving average is $21.94 and its 200-day moving average is $21.36. Immunome, Inc. has a 1-year low of $7.96 and a 1-year high of $27.65. The company has a market cap of $2.45 billion, a P/E ratio of -9.10 and a beta of 2.11.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. On average, equities analysts forecast that Immunome, Inc. will post -2.26 EPS for the current year.

Insider Activity at Immunome

In other news, insider Jack Higgins sold 9,438 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total value of $204,238.32. Following the sale, the insider directly owned 22,000 shares in the company, valued at approximately $476,080. This trade represents a 30.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jean Jacques Bienaime purchased 5,000 shares of Immunome stock in a transaction dated Friday, May 15th. The stock was bought at an average price of $20.70 per share, for a total transaction of $103,500.00. Following the completion of the purchase, the director owned 43,415 shares in the company, valued at $898,690.50. This represents a 13.02% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have sold 139,438 shares of company stock valued at $2,964,664. 7.21% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Craig Hallum raised their target price on shares of Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Truist Financial upgraded shares of Immunome to a “strong-buy” rating in a research note on Monday, May 4th. Wall Street Zen upgraded shares of Immunome from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Finally, Leerink Partners reduced their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research note on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.82.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.